Literature DB >> 26906552

CIZ1 interacts with YAP and activates its transcriptional activity in hepatocellular carcinoma cells.

Liu Lei1, Jinsheng Wu1, Dianhua Gu1, Hui Liu2, Shaochuang Wang3.   

Abstract

Dysregulation of Hippo-Yes-associate protein (YAP) signaling has important roles in the tumorigenesis of hepatocellular carcinoma (HCC). Our previous studies have shown that Cip1 interacting zinc finger protein 1 (CIZ1) activated YAP signaling in the HCC cells and promoted the growth and migration of cancer cells. However, the mechanisms for the activation of YAP signaling by CIZ1 are unknown. In this study, it was found that CIZ1 interacted with the transcriptional factor YAP in HCC cells. The nuclear matrix anchor domain of CIZ1 is responsible for its interaction with YAP. Moreover, CIZ1 enhanced the interaction between YAP and TEAD. Knocking down the expression of CIZ1 impaired the transcriptional activity as well as the biological functions of YAP. Taken together, our study demonstrated that CIZ1 is a positive regulator of YAP signaling, and CIZ1 might be a therapeutic target for HCC.

Entities:  

Keywords:  CIZ1; Cell growth and migration; HCC; YAP

Mesh:

Substances:

Year:  2016        PMID: 26906552     DOI: 10.1007/s13277-016-4866-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

1.  Yes-associated protein expression is a predictive marker for recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  Hua Li; Shouhua Wang; Guoying Wang; ZhiGang Zhang; Xiaocai Wu; Tong Zhang; Binsheng Fu; Guihua Chen
Journal:  Dig Surg       Date:  2015-01-22       Impact factor: 2.588

2.  Hippo pathway key to ploidy checkpoint.

Authors:  Bin Zhao; Kun-Liang Guan
Journal:  Cell       Date:  2014-08-14       Impact factor: 41.582

3.  Cyclin-A-CDK2-mediated phosphorylation of CIZ1 blocks replisome formation and initiation of mammalian DNA replication.

Authors:  Nikki A Copeland; Heather E Sercombe; Rosemary H C Wilson; Dawn Coverley
Journal:  J Cell Sci       Date:  2015-03-03       Impact factor: 5.285

Review 4.  Wnt signaling in liver cancer.

Authors:  Yutaka Takigawa; Anthony M C Brown
Journal:  Curr Drug Targets       Date:  2008-11       Impact factor: 3.465

5.  Variant Ciz1 is a circulating biomarker for early-stage lung cancer.

Authors:  Gillian Higgins; Katherine M Roper; Irene J Watson; Fiona H Blackhall; William N Rom; Harvey I Pass; Justin F X Ainscough; Dawn Coverley
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-16       Impact factor: 11.205

6.  MiR-506 suppresses proliferation of hepatoma cells through targeting YAP mRNA 3'UTR.

Authors:  Yue Wang; Ming Cui; Bao-di Sun; Fa-bao Liu; Xiao-dong Zhang; Li-hong Ye
Journal:  Acta Pharmacol Sin       Date:  2014-08-04       Impact factor: 6.150

7.  YAP activation is an early event and a potential therapeutic target in liver cancer development.

Authors:  Andrea Perra; Marta Anna Kowalik; Elena Ghiso; Giovanna Maria Ledda-Columbano; Luca Di Tommaso; Maria Maddalena Angioni; Carlotta Raschioni; Elena Testore; Massimo Roncalli; Silvia Giordano; Amedeo Columbano
Journal:  J Hepatol       Date:  2014-07-07       Impact factor: 25.083

Review 8.  Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer.

Authors:  Fa-Xing Yu; Bin Zhao; Kun-Liang Guan
Journal:  Cell       Date:  2015-11-05       Impact factor: 41.582

9.  Proteostasis trumps YAP in colon cancer.

Authors:  Tony Avril; Eric Chevet
Journal:  Sci Signal       Date:  2015-10-06       Impact factor: 8.192

10.  miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells.

Authors:  T Higashi; H Hayashi; T Ishimoto; H Takeyama; T Kaida; K Arima; K Taki; K Sakamoto; H Kuroki; H Okabe; H Nitta; D Hashimoto; A Chikamoto; T Beppu; H Baba
Journal:  Br J Cancer       Date:  2015-06-30       Impact factor: 7.640

View more
  8 in total

1.  NUP37, a positive regulator of YAP/TEAD signaling, promotes the progression of hepatocellular carcinoma.

Authors:  Xiaoling Luo; Yuting Liu; Weiguang Feng; Liu Lei; Yemu Du; Jinsheng Wu; Shaochuang Wang
Journal:  Oncotarget       Date:  2017-08-18

2.  A quantitative immunoassay for lung cancer biomarker CIZ1b in patient plasma.

Authors:  Dawn Coverley; Gillian Higgins; Daniel West; Oliver T Jackson; Adam Dowle; Aidan Haslam; Eve Ainscough; Rebecca Chalkley; John White
Journal:  Clin Biochem       Date:  2016-11-17       Impact factor: 3.281

Review 3.  Emerging Roles for Ciz1 in Cell Cycle Regulation and as a Driver of Tumorigenesis.

Authors:  Tekle Pauzaite; Urvi Thacker; James Tollitt; Nikki A Copeland
Journal:  Biomolecules       Date:  2016-12-27

Review 4.  Analysis of the role of the Hippo pathway in cancer.

Authors:  Yanyan Han
Journal:  J Transl Med       Date:  2019-04-08       Impact factor: 5.531

5.  Akt1 and dCIZ1 promote cell survival from apoptotic caspase activation during regeneration and oncogenic overgrowth.

Authors:  Gongping Sun; Xun Austin Ding; Yewubdar Argaw; Xiaoran Guo; Denise J Montell
Journal:  Nat Commun       Date:  2020-11-12       Impact factor: 14.919

Review 6.  Advances in prognostic and therapeutic targets for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The hippo signaling pathway.

Authors:  Geofrey Mahiki Mranda; Zhi-Ping Xiang; Jun-Jian Liu; Tian Wei; Yinlu Ding
Journal:  Front Oncol       Date:  2022-08-12       Impact factor: 5.738

7.  CIZ1-F, an alternatively spliced variant of the DNA replication protein CIZ1 with distinct expression and localisation, is overrepresented in early stage common solid tumours.

Authors:  Dorian R A Swarts; Emma R Stewart; Gillian S Higgins; Dawn Coverley
Journal:  Cell Cycle       Date:  2018-10-06       Impact factor: 4.534

8.  Identification of DHX9 as a cell cycle regulated nucleolar recruitment factor for CIZ1.

Authors:  Urvi Thacker; Tekle Pauzaite; James Tollitt; Maria Twardowska; Charlotte Harrison; Adam Dowle; Dawn Coverley; Nikki A Copeland
Journal:  Sci Rep       Date:  2020-10-22       Impact factor: 4.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.